“Inhibitor Like” Effects of Hematoporphyrin on Factor VIII (Antihaemophilic Globulin)

Summary

The incubation of factor VIII with HP resulted in a progressive loss of factor VIII activity which was dependent on the porphyrin concentration. The rate of reaction was retarded by fibrinogen and glyoxaline, but was not accelerated by reduction in fibrinogen concentration. No increase in factor VIII activity was found when fibrinogen was added after destruction of factor VIII by HP, suggesting irreversibility of factor VIII destruction. The reaction was light but not temperature dependent; in other respects it closely resembled the kinetics observed during factor VIII destruction by naturally occurring anticoagulants and antibody inhibitors of factor VIII.

^* U.S.P.H.S. Research Career Development Award Recipient. Present address: University of Minnesota Hospitals, Minneapolis, Minnesota 55455 U.S.A. Supported in part by U.S.P.H.S. grant H 7150.

• References

• 1 Singer K, Mond E, Hyman J, Levy R. G. Circulating anticoagulants in hemophilia and in hemophilia like diseases. Blood 5: 1135 1950;
• 2 Biggs R, Bidwell E. A method for the study of antihaemophilic globulin inhibitors with reference to six cases. Brit. J. Haemat 5: 379 1959;
• 3 Hougie G. Circulating anticoagulants. Brit. med. Bull 11: 16 1955;
• 4 Margolius A, Jackson D. P, Ratnoff O. D. Circulating anticoagulants: A study of 40 cases and a review of the literature. Medicine 40: 145 1961;
• 5 Ehrenworth L. Spontaneously occurring anticoagulant against antihemophilic globulin in a previously normal subject. Amer. J. Med 34: 272 1963;
• 6 Horowitz H. I, Mitsu F. M. Acquired hemophilia due to a circulating anticoagulant. Report of two cases, with a review of the literature. Amer. J. Med 33: 501 1962;
• 7 Leitner A, Bidwell E, Dike G. W. R. An antihaemophilic globulin (Factor VIII) inhibitor: Purification, characterization and reaction kinetics. Brit. J. Haemat 9: 245 1963;
• 8 Munro F. L, Munro M. P. Electrophoretic isolation of a circulating anticoagulant. J. clin. Invest 25: 814 1946;
• 9 Roberts H. R, Scales M. B, Madison J. T, Webster W. P, Penick G. D. A clinical and experimental study of acquired inhibitors to Factor VIII. Blood 26: 805 1965;
• 10 Davis R. B, Schwartz S. Unpublished observations.
• 11 Solomon H, Zieve P. D. The effect of hematoporphyrin and light on human fibrinogen. J. clin. Invest, (abstract) 44: 1098 1965;
• 12 Biggs R, Macfarlane R. G. Human blood coagulation and its disorders. 3rd. edn.. Blackwell Scientific Publications; Oxford: 1962
• 13 Breckenridge R. T, Ratnoff O. D. Studies on the nature of the circulating anticoagulant directed against antihemophilic factor: with notes on an assay for antihemophilic factor. Blood 20: 137 1962;
• 14 Blum H. F. Photodynamic action and diseases caused by light. Reinhold Publishing Corp.; New York: 1941. American Chemical Society Monography Series.
• 15 Weiss H. J. A study of the cation and pH dependent stability of Factors V and VIII in plasma. Thrombos. Diathes. haemorrh. (Stuttg.) 14: 32 1965;
• 16 Weil L, Gordon W. G, Bucheri A. R. Photooxidation of amino acids in the presence of methylene blue. Arch. Biochem 33: 90 1951;
• 17 Bolande R. P, Wurz L, Ecker E. E. Photodynamic action. II. The effects of photodynamic action on certain properties of human serum. Arch. Path 75: 123 1963;
• 18 McLester W. D, Wagner R. H. Antibody to antihemophilic factor and its lack of reaction with hemophilic plasma. Amer. J. Physiol 208: 499 1965;
• 19 Roberts H. R, Gross G. P, Webster W. P, Dejanov I. I, Penick G. D. Acquired inhibitors of plasma Factor IX. A study of their induction, properties, and neutralization. Amer. J. med. Sci 251: 43 1966;